Alemtuzumab Works Well for Induction Therapy in Renal Transplant Recipients - Renal and Urology News PDF Print
Renal and Urology News
In the first study of its kind, investigators have found that alemtuzumab works better than or as well as either basiliximab or antithymocyte globulin for induction therapy in renal transplant recipients. John Schieszer reports in today's Medical

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.